Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Dacarbazine

Dacarbazine

Dacarbazine is a chemotherapeutic agent used in the treatment of malignant melanoma and Hodgkin's lymphoma.
It functions as an alkylating agent, inhibiting DNA synthesis and cell division.
PubCompare.ai helps researchers optimize Dacarbazine protocols by locating and comparing published procedures from literature, pre-prints, and patents.
Using AI-driven analysis, researchers can identify the most accurate and reproducible Dacarbazine protocols, enhanceing the quality and reliability of their research.

Most cited protocols related to «Dacarbazine»

1
Utilizing the DoD Serum Repository (DoDSR)
Cited 11 times
AFHSC databases were queried to determine the number of serum specimens placed into storage each year as well as the ages of service members at the time of specimen collection. At no time during this project did we seek to obtain personal health data or individually identifiable information. Serum specimens were not accessed.
Algorithmic search method: we initially attempted to identify DoDSR-related publications using a relatively restricted search of the PubMed online database (National Center for Biotechnological Information, http://www.pubmed.org). The text strings “DoDSR,” “DoD serum repository,” “military (or defense) stored (or frozen or banked) serum,” “military (or defense) seroepidemiology,” “military (or defense) seroprevalence,” and “military (or defense) serosurvey” (in English) resulted in 383 unique citations. Forty-eight (48) met the screening criteria—a study conducted by or for the US military using a retrospective serological study design—and were read in full. Reading two of the articles was insufficient to determine that the research used serum from the repository, so the primary authors were contacted; neither of those studies used DoDSR specimens. From our first search method, we identified 25 publications to include in this review.
Intense search method: to ensure that we found as many publications as possible, we obtained digital records of studies from AFHSC’s databases that were supported between 1996 and 2012. For earlier years, only archived paper and email records now exist, and those could not be systematically searched at the time of our review. It should be noted that the current DoDSR inventory management database contains records for all of the specimens collected since 1985. According to the available records, there were 140 serum requests that had been granted (i.e. specimens were removed from the repository and sent to the investigator) between 1996 and 2012. For each request, we used the name of the investigator (or co-investigators if any were available), the date that serum specimens were retrieved and the health condition(s) that the investigators said they were researching to search PubMed (again), the DoD’s online Defense Technical Information Center (DTIC; http://www.dtic.mil) and Google (http://www.google.com). We searched those sources exhaustively and ultimately discovered another 51 articles that used DoDSR specimens. We did not systematically contact investigators who had received serum specimens to determine whether their study had been (or was expected to be) published. This was due to the high mobility of service members and difficulty in contacting individuals years later and because there was no requirement for investigators to notify the AFHSC of publications until 2013. We stopped searching for publications in April 2013 because of limitations in available resource, and included only those that were published through March 2013. There were three studies identified using the algorithmic search method that were not found using the intense search method because AFHSC records prior to October 1996 (the date that the current database was started) were not available.
Seventy-six publications were reviewed to determine the analyte(s) and health condition(s) that were the subject of investigation. No attempt was made at meta-analysis or other statistical observations. We included publications in this review without a priori or post hoc judgments regarding study design, strength of the conclusions, citation indices or journal source. A number of poster presentations and conference abstracts (independent of a related publication) were discovered, but those were not included primarily because full details about the study design, methods and results would not necessarily be available to the average scientific reader. This review was limited to studies that required serum to be taken from the DoDSR after freezing and did not include any publications that resulted from laboratory testing before banking. We did not consider the method by which articles were discovered (by us) as an important factor in our attempt to understand the historical (and potential future) utility of the DoDSR.
Perdue C.L., Cost A.A., Rubertone M.V., Lindler L.E, & Ludwig S.L. (2015). Description and Utilization of the United States Department of Defense Serum Repository: A Review of Published Studies, 1985-2012. PLoS ONE, 10(2), e0114857.
Publication 2015
Conferences Dacarbazine Fingers Military Personnel Range of Motion, Articular Serum Specimen Collection
2
Unresectable Melanoma Treatment Protocol
Cited 9 times
Patients were eligible for inclusion in the study if they had a diagnosis of unresectable stage III or IV melanoma and had received a previous therapeutic regimen containing one or more of the following: dacarbazine, temozolomide, fotemustine, carboplatin, or interleukin-2. Other inclusion criteria were age of at least 18 years; life expectancy of at least 4 months; Eastern Cooperative Oncology Group (ECOG) performance status of 0 (fully active, able to carry on all predisease performance without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work)24 (link); positive status for HLA-A⋆0201; normal hematologic, hepatic, and renal function; and no systemic treatment in the previous 28 days. Exclusion criteria were any other cancer from which the patient had been disease-free for less than 5 years (except treated and cured basal-cell or squamous-cell skin cancer, superficial bladder cancer, or treated carcinoma in situ of the cervix, breast, or bladder); primary ocular melanoma; previous receipt of anti–CTLA-4 antibody or cancer vaccine; autoimmune disease; active, untreated metastases in the central nervous system; pregnancy or lactation; concomitant treatment with any nonstudy anticancer therapy or immunosuppressive agent; or long-term use of systemic corticosteroids.
The protocol was approved by the institutional review board at each participating institution and was conducted in accordance with the ethical principles originating from the Declaration of Helsinki and with Good Clinical Practice as defined by the International Conference on Harmonization. All patients (or their legal representatives) gave written informed consent before enrollment.
Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbé C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A, & Urba W.J. (2010). Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England journal of medicine, 363(8), 711-723.
Publication 2010
Adrenal Cortex Hormones Antibodies, Anti-Idiotypic Autoimmune Diseases Breast Breast Feeding Cancer Vaccines Carboplatin Cells Central Nervous System Cervical Intraepithelial Neoplasia, Grade III Conferences Cytotoxic T-Lymphocyte Antigen 4 Dacarbazine Diagnosis Ethics Committees, Research Eye fotemustine Immunosuppressive Agents Interleukin-2 Kidney Light Malignant Neoplasms Melanoma Neoplasm Metastasis Neoplasms Non-Muscle Invasive Bladder Neoplasms Patients Pregnancy Skin Squamous Cell Carcinoma Temozolomide Therapeutics Treatment Protocols Urinary Bladder
3
Vemurafenib versus Dacarbazine for Metastatic Melanoma
Cited 7 times
From January 2010 through December 2010, a total of 2107 patients underwent screening at 104 centers in 12 countries worldwide. The most common reason for screening failure was a negative test for the BRAF V600 mutation. A total of 675 patients were randomly assigned in a 1:1 ratio to receive either vemurafenib (at a dose of 960 mg twice daily orally) or dacarbazine (at a dose of 1000 mg per square meter of body-surface area by intravenous infusion every 3 weeks) (Fig. A in the Supplementary Appendix, available with the full text of this article at NEJM.org). These patients included 20 with non-V600E mutations (19 with V600K and 1 with V600D), as identified on Sanger and 454 sequencing. Baseline characteristics of the patients were well balanced (Table 1).
Study patients were stratified according to American Joint Committee on Cancer stage (IIIC, M1a, M1b, or M1c), ECOG performance status (0 or 1), geographic region (North America, Western Europe, Australia or New Zealand, or other region), and serum lactate dehydrogenase level (normal or elevated).
Dose reductions for both vemurafenib and dacarbazine were prespecified for intolerable grade 2 toxic effects or worse. The development of cutaneous squamous-cell carcinoma did not require dose modification. The administration of vemurafenib was interrupted until the resolution of the toxic effect to at least grade 1 and restarted at 720 mg twice daily (480 mg twice daily for grade 4 events), with a dose reduction to 480 mg twice daily if the toxic effects recurred. If the toxic effect did not improve to grade 1 or lower or recurred at the 480-mg twice-daily dose, treatment was discontinued permanently. The administration of dacarbazine was interrupted for grade 3 or 4 toxic effects and could be restarted on recovery within 1 week to grade 1 (at full dose) or grade 2 (at 75% dose) or at 75% dose for grade 4 neutropenia or febrile neutropenia. A second dose reduction was allowed, if needed. Antiemetics and granulocyte colony-stimulating factor were administered according to standards at each study center. Treatment was discontinued on disease progression unless continued treatment was in the best interest of the patient in the judgment of the investigator and the sponsor.
Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O’Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T, & McArthur G.A. (2011). Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. The New England journal of medicine, 364(26), 2507-2516.
Publication 2011
Antiemetics BAD protein, human Body Surface Area BRAF protein, human Cancer of Skin Dacarbazine Disease Progression Drug Tapering Electrocorticography Febrile Neutropenia Granulocyte Colony-Stimulating Factor Intravenous Infusion Joints Lactate Dehydrogenase Mutation Neutropenia Patients Serum Squamous Epithelial Cells Staging, Cancer Vemurafenib
4
Vemurafenib vs Dacarbazine in Melanoma
Cited 7 times
The original primary end point was the rate of overall survival. The statistical plan was revised in October 2010 on the basis of phase 1 and 2 efficacy and safety results and after consultation with global regulatory authorities. Under the revised plan, the rates of overall survival and progression-free survival were coprimary end points. The final analysis was planned after 196 deaths, and an interim analysis was planned after 50% of the projected deaths had occurred (Pocock boundary, P≤0.028 at the interim analysis and P≤0.0247 at the final analysis by the log-rank test). According to the revised plan, the final analysis of progression-free survival would be performed at the time of the interim analysis of overall survival. Secondary end points included the confirmed response rate, duration of response, and time to response.
The trial was designed for 680 patients to be randomly assigned to receive either vemurafenib or dacarbazine. The trial had a power of 80% to detect a hazard ratio of 0.65 for overall survival with an alpha level of 0.045 (an increase in median survival from 8 months for dacarbazine to 12.3 months for vemurafenib) and a power of 90% to detect a hazard ratio of 0.55 for progression-free survival with an alpha level of 0.005 (an increase in median survival from 2.5 months for dacarbazine to 4.5 months for vemurafenib). Survival was defined as the time from randomization to death from any cause. Progression-free survival was the time from randomization to documented disease progression or death. We used a two-sided unstratified log-rank test to compare survival rates in the two study groups. Hazard ratios for treatment with vemurafenib, as compared with dacarbazine, were estimated with the use of unstratified Cox regression. We estimated event–time distributions using the Kaplan–Meier method. All reported P values are two-sided, and confidence intervals are at the 95% level. Descriptive statistics are used for adverse events.
This report is based on data as of December 30, 2010. Efficacy analyses were performed in the intention-to-treat population. In order to ensure adequate follow-up for each efficacy end point, patients could be evaluated for the analysis of overall survival, progression-free survival, and confirmed response if they had undergone randomization at least 2, 9, and 14 weeks, respectively, before the cutoff date. The safety analysis was performed in all patients who received a study drug and who had undergone at least one assessment during the study.
Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O’Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T, & McArthur G.A. (2011). Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. The New England journal of medicine, 364(26), 2507-2516.
Publication 2011
Dacarbazine Disease Progression Patients Safety Vemurafenib
5
Comprehensive Medical Record Abstraction for SJLIFE Participants
Cited 5 times
Medical record abstraction for eligible SJLIFE participants is performed using a protocol similar to that utilized in the CCSS.40 (link) This includes abstraction of all chemotherapy received, including cumulative doses for 32 specific chemotherapeutic agents [5-Azacytidine, Bleomycin, Busulfan, Carboplatin, Carmustine, Cisplatin, Cyclophosphamide (IV, PO), Cytarabine (IV, IM, IT, SubQ), Dacarbazine, Dactinomycin, Daunorubicin, Dexamethasone, Doxorubicin, Etoposide (IV, PO), Fludarabine, Fluorouracil, Hydroxyurea, Idarubicin, Ifosfamide, L-Asparaginase, Lomustine, Melphalan, Methotrexate (IV, IM, IT), Nitrogen Mustard, Prednisone, Procarbazine, Teniposide, Thioguanine, Thiotepa, Tretinoin, Vinblastine, Vincristine], surgical procedures, and radiation treatment fields, dose, and energy source. To assure comprehensive ascertainment of health outcomes related to specific treatment exposures, key health events, especially life-threatening organ toxicity, and subsequent malignancies are also obtained. The sources of this information include medical records, Cancer Registry follow-up, and/or contact with next-of-kin for SJCRH patients who survived 10 or more years from diagnosis but subsequently died or are lost to follow-up.
Hudson M.M., Ness K.K., Nolan V.G., Armstrong G.T., Green D.M., Morris E.B., Spunt S.L., Metzger M.L., Krull K.R., Klosky J.L., Srivastava D.K, & Robison L.L. (2010). Prospective Medical Assessment of Adults Surviving Childhood Cancer: Study Design, Cohort Characteristics, and Feasibility of the St. Jude Lifetime Cohort Study. Pediatric blood & cancer, 56(5), 825-836.
Publication 2010
Antineoplastic Agents Asparaginase Azacitidine Bleomycin Busulfan Carboplatin Carmustine Cisplatin Cyclophosphamide Cytarabine Dacarbazine Dactinomycin Daunorubicin Dexamethasone Diagnosis Doxorubicin Etoposide fludarabine Fluorouracil Hydroxyurea Idarubicin Ifosfamide Lomustine Malignant Neoplasms Mechlorethamine Melphalan Methotrexate Operative Surgical Procedures Patients Pharmacotherapy Prednisone Procarbazine Radiotherapy Teniposide Thioguanine Thiotepa Tretinoin Vinblastine Vincristine

Most recents protocols related to «Dacarbazine»

1
Synthesis of Gold Nanoparticles with PEG Functionalization
Dacarbazine (C6H10N6O) ≥ 99%, molar weight: 182.18 g/mol; β-cyclodextrin (C42H70O35) ≥ 97%, molar weight: 1134.98 g/mol; tetrachloroauric acid (HAuCl4*3H2O) ≥ 99.9%, molar weight: 393.83 g/mol; sodium citrate (Na3C6H5O7) ≥ 99%, molar weight: 294.10 g/mol; and nitric acid (HNO3) 70%, molar weight: 63.01 g/mol were provided by Sigma Aldrich (Saint Louis, MO, USA). Hydrochloric acid (HCl) 37%, molar weight: 36.46 g/mol; ethanol (C2H5OH) ≥ 99.9%, molar weight: 46.07 g/mol; hexane (C6H14) ≥ 99.7%, molar weight: 86.18 g/mol; and water (nanopure) were provided by Merck (Darmstadt, Germany). Methoxy PEG Thiol (CH3O-PEG5000-SH) ≥ 95%, molar weight: 5 kDa was provided by JenKem Technology (Plano, TX, USA).
Quintana-Contardo S., Donoso-González O., Lang E., Guerrero A.R., Noyong M., Simon U., Kogan M.J., Yutronic N, & Sierpe R. (2023). Optimizing Dacarbazine Therapy: Design of a Laser-Triggered Delivery System Based on β-Cyclodextrin and Plasmonic Gold Nanoparticles. Pharmaceutics, 15(2), 458.
Publication 2023
Acids Cyclodextrins Dacarbazine Ethanol gold tetrachloride, acid Hydrochloric acid Molar n-hexane Nitric acid Sodium Citrate Sulfhydryl Compounds
2
Melanoma Tumor Inhibition Assay in Mice
Seven-week-old female C57BL/6J mice were obtained from Vital River (Beijing, China). All animal experiments were approved by the Animal Care and Use Committee of the College of Life Sciences, Beijing Normal University. Mice were injected with 100 μL of PBS containing 4 × 105 B16F10 cells and injected into the right hindquarters through hypodermic injection. Mice were randomly divided into 6 groups (n = 5/group), and the first treatments were initiated on the 12th day after inoculation. The dosage units of drugs in animal experiments are usually mg/kg, and two concentration gradients (5 mg/kg and 10 mg/kg) were set up for the experiments. However, because the relative molecular masses of the two drugs are different, the molar amounts of ANV and LbtA5 were unified to ensure that the experimental results were not affected by the number of drug molecules. ANV (139 μmol/kg and 278 μmol/kg) and LbtA5 (139 μmol/kg and 278 μmol/kg) were injected intraperitoneally for 13 consecutive days, and 100 μL of PBS was injected as a negative control and DTIC (40 mg/kg DTIC) (Aladdin, Shanghai, China) as a positive control. Tumor volume was measured every day after the initial injection with calipers and determined as mm3 using the equation A × B2 × 0.52 [38 (link)], where A is the length (mm) and B is the width (mm). After 13 days, the mice were sacrificed, and melanoma tissues were processed for paraffin embedding and stained with hematoxylin and eosin (H&E) (Dingguo).
Zhu J., Li X., Gao W, & Jing J. (2023). Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice. International Journal of Molecular Sciences, 24(4), 3859.
Publication 2023
Animals Cells Dacarbazine Eosin Females Melanoma Mice, House Mice, Inbred C57BL Molar Pharmaceutical Preparations Rivers Tissues Vaccination
3
Melanoma and Skin Cancer Immunotherapy Trials
Before searching the literature, two investigators searched the PROSPERO and INPLASY databases to avoid duplicate topic selections. Then, two investigators independently searched Medline (PubMed), Embase, Cochrane Library, Web of Science, and Clinicaltrials.gov for eligible RCTs published in English within the last 30 years (from 1991.01–2021.11). The main search terms were as follows: (melan* OR skin) AND (pembrolizumab OR nivolumab OR ipilimumab OR immun* OR vaccin* OR dabrafenib OR trametinib OR interferon OR IFN OR vemurafenib OR bevacizumab OR dacarbazine OR chemotherapy) AND (‘Randomized Controlled Trial’ OR ‘Random Allocation’ OR ‘Controlled Clinical Trial’ OR placebo) AND (‘phase II’ OR ‘phase III’ OR ‘phase IV’). The detailed search strategies are provided in Supplemental Appendix 1.
Ba H., Zhu F., Zhang X., Mei Z, & Zhu Y. (2023). Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis. Therapeutic Advances in Medical Oncology, 15, 17588359221148918.
Publication 2023
Bevacizumab cDNA Library dabrafenib Dacarbazine Interferons Ipilimumab Nivolumab pembrolizumab Pharmacotherapy Placebos Skin trametinib Vaccination Vemurafenib
4
Lymphoma Patients' Treatment and Follow-up
Follow-up for lymphoma patients was performed at the hematology clinic and by telephone. The posttherapy lymphoma status was evaluated in lymphoma patients by means of clinical examination and PET/CT scans. Patients will be evaluated every three months for the identification of lymphoma progression. The follow-up was only for 78 patients with lymphoma out of 92 patients. The follow-up could not be performed for these patients as some patients were referred to other centers, some have died, and some had rejected blood samples rewithdrawal. Event-free survival (EFS) measures the time between the end of therapy and the commencement of an event (extranodal involvement). Seven follicular cell lymphoma (FCL) and twenty-eight diffuse large B cell lymphoma (DLBCL) patients' subjects had CHOP therapy (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone) [53 (link)]. In contrast, those with HL had ABVD therapy (Adriamycin, bleomycin, vinblastine, and dacarbazine) and radiation [54 (link)]. Seven patients with chronic lymphocytic leukemia (CLL) underwent various treatments designed based on the therapy indications, stage, and comorbidities. The following strategies were used for CLL: no therapy (approach of watching and waiting if there is no therapy indication); corticosteroids (quiescent CLL with immune cytopenias); FCR chemotherapy (fludarabine, cyclophosphamide, and rituximab) was indicated for CLL progressive illness [49 (link)]. One marginal zone lymphoma (MZL) patient and two mucosa-associated lymphoid tissue (MALT) lymphoma patients had chemotherapy, rituximab, and radiotherapy.
, & Saber M.M. (2023). Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma. Journal of Immunology Research, 2023, 4556586.
Publication 2023
ABVD-I protocol Adrenal Cortex Hormones Adriamycin Bleomycin BLOOD Cells Chronic Lymphocytic Leukemia Cyclophosphamide Dacarbazine DDIT3 protein, human Diffuse Large B-Cell Lymphoma Disease Progression Extranodal Extension fludarabine Hydrochloride, Doxorubicin Lymphoma Lymphoma, Follicular Mucosa-Associated Lymphoid Tissue Lymphoma Oncovin Outpatients Patients Pharmacotherapy Physical Examination Prednisone Radiotherapy Rituximab Scan, CT PET Therapeutics Vinblastine
5
Combination Therapy with Anti-PD-1 and Chemotherapy
The study retrospectively included patients treated with ICIs and chemotherapy who underwent pretreatment 18F-FDG PET/CT at Chongqing Medical University and Chongqing University Cancer Hospital between January 2018 and December 2021. The inclusion criteria were as follows: (1) at least one FDG-avid lesion, defined as a lesion with a higher FDG uptake than the liver; and (2) at least one treatment response evaluation. The exclusion criteria were as follows: (1) ICIs monotherapy; (2) no available pretreatment and follow-up imaging data; (3) < 18 years; (4) no FDG-positive lymphoma lesion; and (5) history of other malignant tumors.
Eighteen patients were treated with anti-PD-1 monoclonal antibodies (mAbs) + ABVD (Anti-PD-1 mAbs: 200 mg, day 1; Doxorubicin: 25 mg/m2, day 2, day 16; Bleomycin: 10 mg/m2, day 2, day 16; Vinblastine: 1.4 mg/m2, day 2, day 16; Dacarbazine: 375 mg/m2, day 2, day 16); 7 with anti-PD-1 mAbs + DHAP (Anti-PD-1 mAbs: 200 mg, day 1; Cisplatin: 100 mg/m2, day 2; Cytarabine: 2 g/m2, day 3; Dexamethasone: 40 mg, day 2-day 5); 5 with anti-PD-1 mAbs + BEACOPP (Anti-PD-1 mAbs: 200 mg, day 1; Bleomycin: 10 mg/m2, day 9; Etoposide: 100 mg/m2, day 2-day 4; Doxorubicin: 25 mg/m2, day 2; Cyclophosphamide: 650 mg/m2, day 2; Vincristine: 1.4 mg/m2, day 9; Procarbazine: 100 mg/m2, day 2-day 8; Prednisone: 40 mg/m2, day 2-day 15) and 1 with anti-PD-1 mAbs + BV (Brentuximab Vedotin: 1.8 mg/kg day 1; Anti-PD-1 mAbs: 200 mg, day 8).
Yang T., Liu S., Zuo R., Liang H., Xu L., Wang Z., Chen X, & Pang H. (2023). Prognostic role of pretreatment 18F-FDG PET/CT and hematological parameters in relapsed/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort study. BMC Medical Imaging, 23, 12.
Publication 2023
ABVD-I protocol Anti-Antibodies Bleomycin Brentuximab Vedotin Cisplatin Cyclophosphamide Cytarabine Dacarbazine Dexamethasone DHAP protocol Doxorubicin Etoposide Liver Lymphoma Malignant Neoplasms Monoclonal Antibodies Patients Pharmacotherapy Prednisone Procarbazine Scan, CT PET Vinblastine Vincristine

Top products related to «Dacarbazine»

1
Dacarbazine by Merck Group
Sourced in United States, Germany
Dacarbazine is a laboratory reagent used in various research applications. It is a cytostatic agent that inhibits cell division and growth. The core function of Dacarbazine is to serve as a tool for researchers studying cellular processes and mechanisms.
2
Cisplatin by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Macao, Italy, France, Canada, Japan, Spain, Czechia, Poland, Australia, India, Switzerland, Sweden, Belgium, Portugal
Cisplatin is a platinum-based medication used as a chemotherapeutic agent. It is a crystalline solid that can be dissolved in water or saline solution for administration. Cisplatin functions by interfering with DNA replication, leading to cell death in rapidly dividing cells.
3
Dacarbazine dtic by Merck Group
Sourced in United States
Dacarbazine (DTIC) is a laboratory product manufactured by Merck Group. It is a chemical compound used in research and development applications. Dacarbazine serves as a building block for various experimental studies and analyses, but its specific function and intended use should not be extrapolated beyond a factual description.
4
Dacarbazine by Medac
Sourced in France, United States
Dacarbazine is a laboratory chemical used for research purposes. It is a white to off-white crystalline powder. Dacarbazine is soluble in water, alcohols, and dimethyl sulfoxide.
5
Facscalibur by BD
Sourced in United States, Germany, United Kingdom, China, Canada, Japan, Italy, France, Belgium, Switzerland, Singapore, Uruguay, Australia, Spain, Poland, India, Austria, Denmark, Netherlands, Jersey, Finland, Sweden
The FACSCalibur is a flow cytometry system designed for multi-parameter analysis of cells and other particles. It features a blue (488 nm) and a red (635 nm) laser for excitation of fluorescent dyes. The instrument is capable of detecting forward scatter, side scatter, and up to four fluorescent parameters simultaneously.
6
Sch772984 by Selleck Chemicals
Sourced in United States, China, Germany, United Kingdom, Switzerland
SCH772984 is a chemical compound used in laboratory research. It functions as a small molecule inhibitor. The core purpose of this product is for use in scientific experimentation and analysis.
7
Penicillin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
8
Streptomycin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
9
Fetal bovine serum (fbs) by Merck Group
Sourced in United States, Germany, United Kingdom, Japan, Italy, China, Macao, Switzerland, France, Canada, Sao Tome and Principe, Spain, Australia, Ireland, Poland, Belgium, Denmark, India, Sweden, Israel, Austria, Brazil, Czechia, Netherlands, Portugal, Norway, Holy See (Vatican City State), New Zealand, Hungary, Senegal, Argentina, Thailand, Singapore, Ukraine, Mexico
FBS, or Fetal Bovine Serum, is a commonly used cell culture supplement. It is derived from the blood of bovine fetuses and provides essential growth factors, hormones, and other nutrients to support the growth and proliferation of a wide range of cell types in vitro.
10
Doxorubicin by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, India, Italy, Poland, Macao, Japan, Sao Tome and Principe, Canada, Spain, Brazil, Australia, Belgium, Switzerland, Singapore, Israel
Doxorubicin is a cytotoxic medication that is commonly used in the treatment of various types of cancer. It functions as an anthracycline antibiotic, which works by interfering with the DNA replication process in cancer cells, leading to their destruction. Doxorubicin is widely used in the management of different malignancies, including leukemia, lymphoma, and solid tumors.

More about "Dacarbazine"

Dacarbazine, also known as DTIC, is a chemotherapeutic agent used in the treatment of malignant melanoma and Hodgkin's lymphoma.
As an alkylating agent, it functions by inhibiting DNA synthesis and cell division, making it an effective cancer treatment.
Researchers can optimize Dacarbazine protocols using PubCompare.ai, which helps locate and compare published procedures from literature, pre-prints, and patents.
This AI-driven analysis can identify the most accurate and reproducible Dacarbazine protocols, enhancing the quality and reliability of cancer research.
Dacarbazine is often used in combination with other chemotherapeutic agents like Cisplatin, Doxorubicin, and Penicillin-Streptomycin (for cell culture applications).
The FACSCalibur flow cytometer is a common tool used to analyze the effects of Dacarbazine on cell viability and proliferation.
SCH772984 is a kinase inhibitor that has been studied in conjunction with Dacarbazine to explore potential synergistic effects.
By leveraging the insights and capabilities of PubCompare.ai, researchers can streamline their Dacarbazine-based studies and improve the quality and reliability of their cancer research.